The clinical benefit of aggressive blood pressure (BP) control in reducing adverse
cardiovascular and renal outcomes is well documented. However, a majority of patients with …

Pharmacological treatment of hypertension represents a cost‐effective way for preventing
cardiovascular and renal complications. To benefit maximally from antihypertensive …

Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease;
however, clinical trial experience suggests that monotherapy is not likely to be successful for …

Blood pressure (BP) control is inadequate worldwide. Many clinical trials suggest that BP is
not satisfactorily controlled using monotherapy in most patients. Free drug or fixed-dose …

Pharmacological treatment of hypertension represents a cost-effective way of preventing
cardiovascular and renal complications. To benefit maximally from antihypertensive …

Despite the widespread availability of several effective classes of drugs, systemic arterial
hypertension remains poorly controlled in the majority of patients worldwide. In this article …

Only 30% of hypertensive patients achieved and maintained adequate blood pressure
control on a single drug in recent clinical trials. For the majority of patients who require two …

Importance of the field: Hypertension is the most common preventable cause of
cardiovascular morbidity and mortality. Despite the availability of a multitude of …

Editor's Note: The American Society of Hypertension is publishing a series of Position
Papers in their official journals throughout the 2008–2011 years. The following Position …

Data from well designed randomized trials have proven the effectiveness of an intensive
approach to hypertension management in reducing morbidity and mortality. Based on these …